Allient (ALNT) Competitors $44.47 -1.15 (-2.52%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$43.98 -0.49 (-1.10%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALNT vs. TXG, EYPT, AEHR, TRNS, LAB, CTKB, SENS, QSI, FEIM, and MASSShould you be buying Allient stock or one of its competitors? The main competitors of Allient include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Transcat (TRNS), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Allient vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Aehr Test Systems Transcat Standard BioTools Cytek Biosciences Senseonics Quantum-Si Frequency Electronics 908 Devices 10x Genomics (NASDAQ:TXG) and Allient (NASDAQ:ALNT) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Is TXG or ALNT more profitable? Allient has a net margin of 2.75% compared to 10x Genomics' net margin of -13.13%. Allient's return on equity of 9.97% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Allient 2.75%9.97%4.67% Which has stronger earnings & valuation, TXG or ALNT? Allient has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.46-$182.63M-$0.70-17.23Allient$529.97M1.42$13.17M$0.8651.71 Which has more risk and volatility, TXG or ALNT? 10x Genomics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, Allient has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Does the media favor TXG or ALNT? In the previous week, 10x Genomics and 10x Genomics both had 4 articles in the media. 10x Genomics' average media sentiment score of 1.53 beat Allient's score of 0.84 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Allient 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in TXG or ALNT? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 15.6% of Allient shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate TXG or ALNT? 10x Genomics currently has a consensus price target of $13.65, indicating a potential upside of 13.22%. Allient has a consensus price target of $35.00, indicating a potential downside of 21.30%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Allient.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 8 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33Allient 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Summary10x Genomics beats Allient on 8 of the 15 factors compared between the two stocks. Get Allient News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNT vs. The Competition Export to ExcelMetricAllientELEC IndustryComputer SectorNASDAQ ExchangeMarket Cap$773.12M$6.08B$32.48B$10.41BDividend Yield0.26%2.37%3.14%4.62%P/E Ratio51.7126.54456.8326.42Price / Sales1.422.621,801.82168.33Price / Cash15.0424.4338.1361.52Price / Book2.832.607.306.39Net Income$13.17M$177.35M$810.65M$271.13M7 Day Performance-6.99%-1.07%0.47%0.93%1 Month Performance-4.55%2.60%7.79%7.52%1 Year Performance135.04%20.34%24,248.71%30.06% Allient Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNTAllient2.4101 of 5 stars$44.47-2.5%$35.00-21.3%+129.2%$773.12M$529.97M51.712,525TXG10x Genomics3.8932 of 5 stars$13.04flat$13.65+4.7%-47.5%$1.62B$610.78M-18.631,240Positive NewsEYPTEyepoint Pharmaceuticals1.7825 of 5 stars$13.36+0.8%$26.86+101.0%+68.8%$913.29M$43.27M-4.99120Positive NewsAEHRAehr Test Systems1.9465 of 5 stars$32.53+8.6%N/A+161.8%$897.57M$58.97M-250.2190TRNSTranscat3.786 of 5 stars$74.37-1.4%$112.20+50.9%-41.9%$703.12M$278.42M52.011,245Positive NewsLABStandard BioTools2.8884 of 5 stars$1.40flat$1.55+10.7%-33.5%$534.79M$174.43M-4.38620CTKBCytek Biosciences1.9699 of 5 stars$3.86+2.1%$5.60+45.1%-34.5%$480.91M$200.45M-77.20500Positive NewsSENSSenseonics2.3351 of 5 stars$0.46-0.3%$1.54+235.1%+35.8%$373.78M$25.47M-3.5390QSIQuantum-Si1.8891 of 5 stars$1.70+13.3%$3.48+104.4%+72.1%$303.74M$3.06M-2.50150Trending NewsGap UpHigh Trading VolumeFEIMFrequency Electronics3.3214 of 5 stars$29.89-2.8%$43.00+43.9%+145.0%$299.69M$69.81M13.05200MASS908 Devices2.3176 of 5 stars$7.55+3.4%$8.00+6.0%+107.7%$261.79M$59.63M-13.9860 Related Companies and Tools Related Companies 10x Genomics Alternatives Eyepoint Pharmaceuticals Alternatives Aehr Test Systems Alternatives Transcat Alternatives Standard BioTools Alternatives Cytek Biosciences Alternatives Senseonics Alternatives Quantum-Si Alternatives Frequency Electronics Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allient Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
